# AortaAlertAI - AAA Rupture Prediction Platform

## Venture Spec

**Date:** 2026-03-02
**Status:** GO - 8.17/10
**Category:** Healthcare AI / Vascular Surgery / Clinical Decision Support

---

## Name

**AortaAlertAI - AAA Rupture Prediction & Surveillance Platform**

---

## Core Concept

AI-powered platform for vascular surgeons that detects abdominal aortic aneurysm (AAA) growth acceleration, predicts rupture risk, and sends real-time alerts for pre-emptive repair. Uses longitudinal CT analysis with machine learning to identify subtle signs of instability before diameter threshold is reached.

---

## Problem Statement

### The Clinical Challenge

- **1.5M Americans** have abdominal aortic aneurysms
- **15,000-30,000 AAA ruptures annually** in the United States
- **80% mortality rate** when rupture occurs (most die before reaching hospital)
- **Current surveillance is crude:** Diameter >5.5cm = surgery recommendation
- **No early warning:** Rapid expansion can happen between scheduled scans
- **Rupture is catastrophic:** Most patients die, survivors have emergency surgery morbidity

### The Limitations of Current Practice

```
Current Surveillance Protocol:
- AAA <4.0cm: Scan annually
- AAA 4.0-4.9cm: Scan every 6 months
- AAA ≥5.0cm: Surgical referral

Problem: Rupture CAN occur at 4.5cm if rapid expansion.
Problem: Patient may be 3 months from next scan when growth accelerates.
Problem: Diameter ignores wall stress, morphology, growth trajectory.
```

### The Clinician Experience

```
"I had a patient with a 4.7cm AAA. His next scan was in 4 months.
He ruptured at home 6 weeks later. If we'd caught the growth acceleration,
we could have done elective EVAR and he'd be alive today."
- Vascular Surgeon
```

---

## Target Vertical

### Primary: Vascular Surgery

| Role | Pain Points | Decision Maker |
|------|-------------|----------------|
| Vascular Surgeons | Rupture anxiety, missed growth, liability | Primary User |
| vascular Medicine Physicians | Surveillance management, referral timing | Primary User |
| Interventional Radiologists | EVAR/TEVAR planning, case timing | Secondary User |

### Secondary: Hospital Administration

| Role | Pain Points | Decision Maker |
|------|-------------|----------------|
| Hospital C-Suite | Rupture mortality, emergency surgery costs | Budget Approver |
| Quality/Safety Officers | AAA mortality metrics, bundled care | Champion |
| Radiology Directors | CT surveillance workflow | Technical Gatekeeper |

---

## Why Now

### 1. Technology Readiness

- **CT aortic segmentation is proven** - multiple peer-reviewed models, open source implementations
- **Longitudinal ML techniques matured** - time-series analysis, growth curve modeling
- **PACS integration is standard** - DICOM interoperability, HL7/FHIR APIs
- **Cloud infrastructure** - HIPAA-compliant medical imaging processing

### 2. Data Availability

- **Every vascular practice** has 5-10 years of surveillance CTs
- **Rupture outcomes tracked** in morbidity & mortality conferences
- **Public datasets available** - TCIA, other medical imaging repositories

### 3. Clinical Urgency

- **AAA rupture mortality is 80%** - highest urgency in vascular surgery
- **EVAR/TEVAR are mature** - elective repair is safe and effective
- **Screening programs expanded** - Medicare covers one-time AAA ultrasound for men 65-75 who ever smoked

### 4. Regulatory Tailwinds

- **SaMD Class II pathway** - clinical decision support (moderate risk)
- **FDA breakthrough program** - for life-saving technologies
- **Quality measure pressure** - hospitals track AAA mortality

---

## AI Advantage

### Core Capabilities

| Capability | Technology | Clinical Impact |
|------------|------------|-----------------|
| **Growth Acceleration Detection** | Longitudinal time-series ML on CT measurements | Detect rapid expansion 2-3 months before rupture |
| **Morphological Instability** | Computer vision for wall irregularities, thrombus changes | Identify high-risk features beyond diameter |
| **Personalized Risk Trajectory** | Multi-timepoint growth curve modeling | Patient-specific surveillance intervals |
| **Real-time Alerting** | Automated risk scoring + push notifications | Immediate surgeon notification |
| **Retrospective Analysis** | Batch processing of historical surveillance series | Identify at-risk patients in existing panel |

### Technical Differentiation

```
Current Standard of Care:
- Single-timepoint diameter measurement
- Population-based thresholds (5.5cm)
- Static surveillance intervals
- Manual radiologist measurement

AortaAlertAI:
- Multi-timepoint growth curve analysis
- Patient-specific trajectory modeling
- Dynamic surveillance recommendations
- Automated growth acceleration detection
- Morphological risk features (wall stress, thrombus)
```

---

## Viral Mechanism

### Conference Strategy

- **SVS (Society for Vascular Surgery)** - 2,000+ attendees, annual meeting
- **Vascular Annual Meeting** - Joint SVS/ESVS event
- **Regional vascular societies** - Western Vascular, Eastern Vascular

### Viral Messaging

> "AI detected rapid growth acceleration 6 weeks before rupture. Patient had elective EVAR and is alive today."
>
> "Our practice reduced AAA mortality by 40% with longitudinal growth monitoring."

### Case Study Format

- **Before/After:** Patient with rapid acceleration caught early
- **Saved Life:** Specific story of prevented rupture
- **Practice Impact:** Mortality reduction, liability protection
- **ROI:** 1 prevented rupture = $100K+ savings vs emergency care

### Academic Validation

- **Journal of Vascular Surgery** - Case series, validation studies
- **SVS Quality Initiative** - Integration with VQI database
- **Morbidity & Mortality Conference** - Live case reviews

---

## Revenue Model

### Pricing Tiers

| Tier | Annual Price | Features | Target |
|------|--------------|----------|--------|
| **Starter** | $30,000/year | Growth acceleration detection, alerts for 50 patients | Small practices (1-3 surgeons) |
| **Professional** | $60,000/year | Full suite + retrospective panel analysis + VQI integration | Medium practices (4-10 surgeons) |
| **Enterprise** | $100,000/year | Multi-site + API access + custom models + research collaboration | Large health systems |

### Unit Economics

| Metric | Value | Notes |
|--------|-------|-------|
| **CAC** | $15,000 | SVS conferences, direct sales |
| **ARPU** | $60,000 | Professional tier average |
| **LTV** | $180,000 | 36-month retention (very high switching costs) |
| **Gross Margin** | 85% | Software, minimal marginal cost |
| **LTV:CAC** | 12:1 | Strong unit economics |

### Sales Cycle

- **Pilot:** 4-6 weeks (retrospective validation, demonstrate on practice data)
- **Implementation:** 2-4 weeks (PACS integration, patient data upload)
- **Contract:** 12-36 month commitments (annual recurring)

---

## MVP in 8 Weeks

### Weeks 1-2: Data & Partnership

**Goal:** Secure one vascular surgery partnership, collect surveillance CT data

- Identify and pitch one vascular surgery practice (academic or high-volume private)
- IRB approval for retrospective data analysis
- Extract surveillance CT series (minimum 100 patients with 3+ scans)
- Define data schema and preprocessing pipeline

**Deliverable:** De-identified surveillance CT dataset

### Weeks 3-5: Model Development

**Goal:** Build growth acceleration detection ML with >0.80 AUC

- Feature engineering (diameter, volume, growth rate, acceleration, morphology)
- Model training (XGBoost, LightGBM for time-series)
- Validation with time-based cross-validation (train on earlier scans, test on later)
- Calibration for clinical interpretability

**Deliverable:** Trained growth acceleration model with performance report

**Validation Metrics:**
- AUC-ROC > 0.80 for predicting rapid growth (>5mm/year)
- Detection acceleration 2-3 months before clinical detection
- Sensitivity > 0.75, Specificity > 0.80
- Calibration error < 0.10

### Weeks 6-7: Pilot & Validation

**Goal:** One practice pilot, validate against known outcomes

- Deploy model on practice's historical surveillance data
- Compare model predictions vs. actual outcomes (rupture, repair)
- Measure lead time improvement
- Gather surgeon feedback on UI/UX

**Deliverable:** Pilot validation report with case studies

**Pilot Metrics:**
- Detection of 80%+ of rapid growth cases before next scheduled scan
- 3+ month average lead time improvement
- Surgeon satisfaction score > 4/5

### Week 8: Refinement & Demo

**Goal:** Refine model, prepare SVS conference demo

- Model refinement based on pilot feedback
- Build demo interface for conference presentation
- Create case study materials ("Saved Life" stories)
- Prepare SVS abstract submission

**Deliverable:** Conference-ready demo + 2-3 case studies

---

## Tech Stack

### Backend & AI

```
Language: Python 3.11+
Framework: FastAPI
AI/ML: Scikit-learn, XGBoost, PyTorch (LSTM option)
Medical Imaging: SimpleITK, PyDICOM, MONAI
Data: Pandas, NumPy
```

### Integrations

```
PACS Systems:
- GE Healthcare Centricity
- Philips IntelliSpace Portal
- Siemens Healthineers
- Agfa Impax

Vascular Quality Initiative (VQI):
- SVS VQI database integration
- M&M case tracking

EHR Systems:
- Epic (FHIR API)
- Cerner (FHIR)
```

### Infrastructure

```
Cloud: AWS (us-east-1, us-west-2)
Compute: ECS Fargate (HIPAA compliant)
Storage: S3 (encrypted, DICOM storage)
Database: PostgreSQL (RDS encrypted)
Monitoring: CloudWatch, Datadog
Security: VPC, encryption at rest/transit, audit logs
```

### Compliance

```
HIPAA: BAA with all vendors
SOC 2: Type II certification (planned Year 2)
FDA: SaMD Class II pathway (clinical decision support)
```

---

## Market Opportunity

### Market Size

| Segment | Estimate | Notes |
|---------|----------|-------|
| US Vascular Surgeons | 5,000 | Primary target |
| AAA Surveillance Patients | 1.5M | Growing with screening |
| Annual AAA Repairs | 50,000+ | EVAR + open repair |
| Annual AAA Ruptures | 15,000-30,000 | Target for prevention |

### Revenue Potential

- **TAM:** 5,000 practices × $60,000 = $300M ARR
- **SAM:** 1,000 high-volume practices = $60M ARR
- **SOM (3-year):** 50 practices = $3M ARR

### International Expansion

- **Europe:** 25,000 vascular surgeons, similar AAA prevalence
- **Japan:** High EVAR adoption, aging population
- **Australia:** Developed vascular surgery market

---

## Competitive Threat

### Direct Competitors

| Competitor | Strengths | Weaknesses |
|------------|-----------|------------|
| **TeraRecon (iNVTX)** | Advanced visualization, established | No longitudinal ML, diameter-based |
| **Philips IntelliSpace Portal** | PACS integration, workflow | Population thresholds, no acceleration |
| **HeartFlow** (plumbing) | Proven ML in cardiovascular | Focused on CAD, not AAA |
| **Radiology AI startups** | Segmentation algorithms | Single-scan focus, no longitudinal |

### Differentiation Strategy

**AortaAlertAI is the only platform with:**

1. **Longitudinal growth acceleration ML** - Multi-timepoint analysis
2. **Patient-specific trajectory modeling** - Personalized vs population
3. **Real-time rupture risk alerts** - Proactive notification
4. **Retrospective panel analysis** - Identify at-risk existing patients
5. **VQI integration** - Quality metric tracking

**Competitive moat:**
- **Longitudinal data requirements** - Need 3+ scans per patient
- **Rupture outcome tracking** - Only vascular practices have this
- **Time-series ML expertise** - Harder than single-scan CV
- **Clinical workflow integration** - Designed for vascular surgeons

---

## Risk Factors

### Clinical Risks

| Risk | Impact | Mitigation |
|------|--------|------------|
| **False Positives** | Unnecessary surgery, patient anxiety | Conservative thresholds, transparent uncertainty |
| **False Negatives** | Missed rupture, liability | High sensitivity calibration, clear disclaimers |
| **Model Drift** | Performance degradation | Continuous monitoring, retraining pipelines |
| **CT availability** | Not all practices have surveillance data | Start with high-volume practices, partner with imaging centers |

### Commercial Risks

| Risk | Impact | Mitigation |
|------|--------|------------|
| **Radiology AI competition** | Large players enter AAA | Focus on longitudinal (harder), clinical workflow |
| **Slow adoption** | Conservative vascular surgeons | Pilot validation, case studies, key opinion leaders |
| **PACS integration complexity** | Long deployment cycles | Start with DICOM export, cloud processing |
| **Reimbursement uncertainty** | No CPT code | Practice-funded, avoid cost narrative |

### Regulatory Risks

| Risk | Impact | Mitigation |
|------|--------|------------|
| **FDA SaMD requirements** | Expensive pathway | Clinical decision support (lower risk), IDE preparation |
| **Liability exposure** | Missed rupture = lawsuit | Clear disclaimers, surgeon-in-the-loop, insurance |
| **HIPAA compliance** | Breach penalties | Security-first architecture, third-party audits |

---

## Go/No-Go Decision

### Score: 8.17/10 - **GO**

### Strengths

- **Highest pain score (10)** - AAA rupture = 80% mortality, catastrophic outcome
- **Highest AI-native score (9)** - Longitudinal growth acceleration ML is novel and defensible
- **Strong defensibility (9)** - Longitudinal data + rupture outcomes are rare and proprietary
- **Proven technical feasibility** - CT segmentation + time-series ML are mature
- **Clear clinical value** - 1 prevented rupture = life saved + $100K+ saved

### Weaknesses

- **Moderate market (5K)** - Smaller than primary care but concentrated
- **Complex PACS integration** - Healthcare IT always slower
- **Liability concerns** - Missed rupture = high stakes

### Why This Scores 8.17

This venture scores highly because it hits multiple proven patterns:

1. **Time-critical mortality urgency** - 80% mortality = highest stakes
2. **Pure ML prediction** - Longitudinal growth acceleration, not GPT wrapper
3. **Data moat** - Multi-timepoint CT + rupture outcomes = scarce
4. **Avoidance value** - Prevents catastrophic outcome (rupture)
5. **Viral case studies** - "AI prevented rupture" = compelling story

---

## Critical Success Factors

### 1. Clinical Leadership

- **Hire vascular surgeons** as co-founders or advisors
- **Build medical advisory board** with AAA specialists
- **Understand surveillance workflow** deeply (intervals, thresholds)

### 2. Hospital Partnerships

- **Partner with one high-volume practice** for retrospective data + pilot
- **Select academic center** (research interest, data quality, volume)
- **Build reference case study** for sales leverage

### 3. Lead with Growth Acceleration

- **Growth acceleration is the differentiator** - diameter measurement is commodity
- **Lead time is measurable** - clear ROI (caught X months early)
- **Personalized surveillance** - dynamic intervals vs one-size-fits-all

### 4. Focus on Avoidance

- **"Prevented rupture"** story > "Better monitoring"
- **Cost savings** - emergency rupture care = $100K+
- **Liability protection** - documented monitoring is defense

### 5. Conference Relationships

- **Build SVS presence** early
- **Submit abstracts** for Vascular Annual Meeting
- **Network with vascular surgeon champions** (KOLs)

---

## Next Steps

### Immediate (Week 1)

1. **Form clinical advisory board** - Recruit 2-3 vascular surgeons
2. **Identify pilot practice** - Academic or high-volume private
3. **Draft IRB protocol** - For retrospective data access
4. **Design data schema** - CT series, outcomes, annotations

### Short-term (Month 1-2)

1. **Secure first practice partnership** - Sign data agreement
2. **Extract and validate dataset** - 100+ patients with 3+ surveillance CTs
3. **Train initial model** - Target >0.80 AUC for growth acceleration
4. **Build retrospective analysis tool** - Batch processing

### Medium-term (Month 3-4)

1. **Run pilot validation** - Measure lead time vs. standard of care
2. **Build alert dashboard** - Real-time risk notification
3. **Gather feedback** - Iterate on UI/UX for surgeons
4. **Prepare SVS abstract** - Conference submission

### Long-term (Month 5-8)

1. **Convert pilot to customer** - First commercial contract
2. **Build sales collateral** - Case studies, ROI calculator
3. **Hire sales leader** - Healthcare IT experience
4. **Scale to 3-5 practices** - Reference customer base

---

## Conclusion

**80% mortality + longitudinal ML + growth acceleration detection = life-saving urgency.**

AortaAlertAI addresses one of the most urgent problems in vascular surgery with a combination of:

- **Proven ML technology** (CT segmentation + time-series analysis)
- **Clear clinical value** (pre-emptive repair before rupture)
- **Strong data moat** (longitudinal surveillance + rupture outcomes)
- **Compelling case studies** ("AI prevented rupture")

The 8.17/10 score reflects the exceptional urgency, novel AI approach, and defensible data requirements. While competition exists from radiology AI companies, the longitudinal focus and vascular surgeon workflow integration provide meaningful differentiation.

**Go build AortaAlertAI. Lives depend on it.**

---

*Venture Spec Generated: 2026-03-02*
*Status: GO - 8.17/10*
